InvestWiser

Oncoinvent ASA

ONCINOslo BørsHealthcareMarket value 436 m NOK
71.20NOK +0.3%
last day · Price as of 18 November 2026

The answer first

Does Oncoinvent beat the market?

Yes, Oncoinvent has beaten the market over the last year.

Oncoinvent+41.8%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 36% of Nordic stocks

    • Quality65
    • Value3
    • Trend66

    No. 89 of 195 in healthcare

Max for seven days

Follow Oncoinvent with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Oncoinvent

From today, at a price of 71.20 NOK. Write why you follow Oncoinvent, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Oncoinvent

Your first answer is free, no account needed.

Do you own Oncoinvent, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Oncoinvent and a few more. Free, no card.

Past year against the exchange and Super Stock
Oncoinvent+30.9%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Oncoinvent has risen 41.8% over the past year, including dividends.
  • Overall, Oncoinvent ranks better than 36% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 99.9%. The price is 100.0% below its peak now.

What do analysts think of Oncoinvent?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

36

Quality, value and trend together. Better than 36% of Nordic stocks.

No. 89 of 195 in healthcare

Quality65
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 96 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.03
  • Asset turnoverSales divided by everything the company owns0.04
  • Return on equityProfit divided by equity−133.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value3
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 177 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity4.0
  • P/SPrice divided by sales60.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend66
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 59 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−14.4%
  • 6 months+52.5%
  • 9 months+56.5%
  • 12 months+41.8%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+4.4%
3 years, per year
−61.0%
5 years, per year
−77.0%
Year to date
+45.0%
Largest fall, 3 years
−99.9%
From a peak to the bottom
From the peak now
−100.0%
How far the price is from the peak
Volatility, 1 year
114.8%
How much the price swings over a year
Beta, 1 year
0.62
How much the price moves when the market moves

Return with dividends reinvested.

About Oncoinvent

Oncoinvent ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 42 employees.

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

See the full analysis of Oncoinvent.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market